Kallisio Patient-tailored Oral Stent for Head and Neck Cancer (HNC) Treatment Receives FDA Clearance
Kallisio , focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.
- Kallisio , focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.
- Customized for each patient, the Stentra oral immobilization stent effectively directs radiation to the target tumor area while reducing harmful impact to surrounding tissue.
- By integrating patient oral data with advanced 3D printing, Stentra is meticulously tailored to mitigate target positioning discrepancies associated with radiotherapy methods like IMRT (intensity-modulated radiation therapy).
- A Stentra device immobilizes tongue, lips, and other OARs (organs at risk), keeping them clear of the high-dose radiation target zone.